Drug Trial Radar · NCT00746447
Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)
Last checked: Nov 19, 2026Latest source record: Jun 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
648
Actual
Start
May 2005
Primary completion
Apr 2007
Study completion Mar 2008
Sponsor
- Lead sponsor
- Dr. Falk Pharma GmbHIndustry
- Sponsor type
- Industry
- First posted
- Sep 4, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs. three times daily 0.5 g mesalazine granules for maintenance of remission in patients with ulcerative colitis
Conditions
- Colitis, Ulcerative
- Recurrence
Interventions
mesalamine granulesDrug
3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
mesalamine granulesDrug
1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
mesalamine granulesDrug
0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients still in clinical remission at the final/withdrawal examination, with clinical relapse defined as a CAI >4 with an increase of ≥3 points from baseline.Time frame: week 52 or premature withdrawal
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Evangelisches Krankenhaus Kalk, Medical Dept.
Cologne, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.